Puma Biotechnology to Present at Cowen’s Health Care Conference
03 March 2017 - 8:20AM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company, announced that Alan H. Auerbach, Chairman, Chief Executive
Officer, President and Founder of Puma, will provide an overview of
the Company at 3:20 p.m. EST on Monday, March 6, at the Cowen and
Company 37th Annual Health Care Conference. The conference will be
held at the Boston Marriott Copley Place.
A live webcast of the presentation will be available on the
Company’s website at www.pumabiotechnology.com. The presentation will
be archived on the website and available for 30 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. The Company in-licenses the global
development and commercialization rights to three drug
candidates—PB272 (neratinib (oral)), PB272 (neratinib
(intravenous)) and PB357. Neratinib is a potent irreversible
tyrosine kinase inhibitor that blocks signal transduction through
the epidermal growth factor receptors, HER1, HER2 and HER4.
Currently, the Company is primarily focused on the development of
the oral version of neratinib, and its most advanced drug
candidates are directed at the treatment of HER2-positive breast
cancer. The Company believes that neratinib has clinical
application in the treatment of several other cancers as well,
including non-small cell lung cancer and other tumor types that
over-express or have a mutation in HER2.
Further information about Puma Biotechnology may be found at
www.pumabiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements that
involve risks and uncertainties that could cause the Company's
actual results to differ materially from the anticipated results
and expectations expressed in these forward-looking statements.
These statements are based on current expectations, forecasts and
assumptions, and actual outcomes and results could differ
materially from these statements due to a number of factors, which
include, but are not limited to, the risk factors disclosed in the
periodic reports filed by the Company with the Securities and
Exchange Commission from time to time. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. The Company assumes no obligation
to update these forward-looking statements, except as required by
law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170302006219/en/
Puma Biotechnology, Inc.Alan H. Auerbach or Mariann Ohanesian,
+1
424-248-6500info@pumabiotechnology.comir@pumabiotechnology.comorRusso
PartnersDavid Schull or Darren Chia, +1
212-845-4242david.schull@russopartnersllc.comdarren.chia@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Apr 2024 to May 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From May 2023 to May 2024